#ASH24 great work by Ross Firestone (who’s basically an assoc prof at Memorial Sloan Kettering Cancer Center despite still being a fellow 😉 ) Regardless of MRD status by NGF (e.g., tumor biology), clear T cell profiles (e.g., immune biology) matter too. This can predict #MMsm PD even if MRD-neg!

Annual ASH selfie with Naveen Pemmaraju, MD Great to see you! #ASH24 #mmsm #mpnsm

The Memorial Sloan Kettering Cancer Center 13th Annual #BoardReview & Comprehensive Update in #Hematology and #MedicalOncology, condensed into an intensive 3.5-day program, provides an up-to-date review of the diagnosis, staging, and management of neoplastic diseases, including solid tumors and

1/ 🚨New research alert! 🚨Our study in Blood Cancer Journal shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma (MM), with Ross Firestone, Malin Hultcrantz MD PhD, Larry Norton, Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰, and the rest of the Memorial Sloan Kettering Cancer Center team! 🧵👇

Near 100% responses represents a serious opportunity for patients with newly diagnosed multiple myeloma

The 8th paper from the iStopMM study was published in Blood Cancer Journal in 2022. This study examines serum free light chain (FLC) reference intervals in kidney disease. We propose new eGFR-based reference intervals to improve accuracy. 📜📷#iStopMM #MGUS

We're excited to kick off the Memorial Sloan Kettering Cancer Center 2025 Update in #Hematology and #MedicalOncology and 13th Annual Board Review this Friday. Join us for an engaging program led by renowned faculty. Explore the full agenda at bit.ly/HemOnc2025. #MSKHemOncCME ILSON David,

Register for our #Myeloma #MRD meeting to hear from Malin Hultcrantz MD PhD on ClonoSEQ MRD assay 🩸💻 👉 us06web.zoom.us/webinar/regist… 🗓️ 11 April 📍Online #MultipleMyeloma #MMsm HealthTree Foundation Sylvester Comprehensive Cancer Center Multiple Myeloma RF International Myeloma Foundation

Dr. Malin Hultcrantz (Malin Hultcrantz MD PhD, Memorial Sloan Kettering Cancer Center) presents a dynamic risk score model for SMM. Early changes in M-protein and FLC-ratio can better predict progression to MM, even among patients classified as low risk at diagnosis. #DAVAWhistler #Oncology

Teclistamab not working? Add a CELMoD twist! Dr. Malin Hultcrantz MD PhD explores teclistamab+ mezigdomide combo to fight T-cell exhaustion & BCMA escape in RRMM Trial opens May 2025-Watch this space! #Myeloma #CELMoD #DAVAWhistler

Shout out also to Theresia Akhlaghi! #mmsm

MMRF’s Chief Medical Officer Hearn Jay Cho MD, PhD, joined a powerful panel on the future of MRD in myeloma at #MRD2025 in Miami — featuring voices from patients, physicians & scientists. #MyelomaMRD2025 #MultipleMyeloma #CancerResearch #HealthEquity C. Ola Landgren, M.D. Sylvester Comprehensive Cancer Center

Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Malin Hultcrantz MD PhD oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma CancerWorld

Congrats Theresia Akhlaghi 👏🏼👏🏼👏🏼

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Myeloma Paper of the Day, June 28th, Suggested by Robert Orlowski (Robert Z. Orlowski) Malin Hultcrantz MD PhD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #RRMM #Myeloma CancerWorld

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing ow.ly/1B5H50WmAsF #plasmacelldisorders

Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. - Aim for good disease control in standard-risk myeloma - Aim for MRD negativity in high-risk myeloma - Avoid IMiDs after transplant if possible - Reduce immunosuppression

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia - Kidney International kidney-international.org/article/S0085-…